Abstract
Despite overall progress in global TB control, the rising burden ofmultidrug-resistant TB (MDR-TB) threatens to undermine efforts to end theworldwide epidemic. Of the 27 countries classified as high burden for MDR-TB, 17 are in 'low' or 'low-middle' income countries. Shorter, all oral and less toxic multidrug combinations are required to improve treatment outcomes in these settings. Suitability for safe co-administration with HIV drugs is also desirable. A range of strategies and several new drugs (including bedaquiline, delamanid and linezolid) are currently undergoing advanced clinical evaluations to define their roles in achieving these aims. However, several clinical questions and logistical challenges need to be overcome before these new MDR-TB treatments fulfil their potential.
| Original language | English |
|---|---|
| Article number | trv107 |
| Pages (from-to) | 163-172 |
| Number of pages | 10 |
| Journal | Transactions of the Royal Society of Tropical Medicine and Hygiene |
| Volume | 110 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Mar 2016 |
Keywords
- Bedaquiline
- Delamanid
- Extensively drug-resistant
- Linezolid
- Multidrug-resistant
- Tuberculosis
Access to Document
- Sloan_2016_Multidrug-resistantTB_TransRoySocTropMed&Hyg_CC
© The Author 2016. Published by Oxford University Press on behalf of Royal Society of Tropical Medicine and Hygiene. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.